Zoledronic Acid and Leuprolide Acetate Affect Du-145 Migration towards Stem Cell Conditioned Medium by La Montagna, G. et al.
163 J Cancer Biol Therap, 4(1): 163-171 (2018)  
Journal of Cancer Biology and Therapeutics
Zoledronic Acid and Leuprolide Acetate Affect 
Du-145 Migration towards Stem Cell Conditioned 
Medium
La Montagna G, Sibille G, Bertolini F, Mognetti B*
Department of Clinical and Biological Science, University of Turin, Italy
 
*Correspondence: Barbara Mognetti, Department of Clinical and Biological Science, University of Turin, Regione 
Gonzole 10, 10043 Orbassano (To), Italy, Tel: +39 0116705439; Fax: +39 0119038639; 
E-mail: barbara.mognetti@unito.it
Rec date: Mar 27, 2018; Acc date: Jun 20, 2018; Pub date: Jun 26, 2018
Abstract
Prostate cancer (PCa) is the most frequent genitourinary tumour and the third specific death cause, mostly because 
of bone metastasis. Currently, PCa is treated with GnRH analogues (leuprolide acetate-LA) and bisphosphonates 
(zoledronic acid-ZA) often in association. Thus, the aim of this work has been to study, in vitro, the effects of these 
drugs on cell line derived from PCa (DU-145).  Particularly, we focused on some crucial aspects that drugs might play 
in tumor evolution and metastatization, by interfering with vitality, migration and interactions with bone cells. ZA 
cytotoxicity has been confirmed on DU-145 after 48-hours incubation at 5 μM, while LA cytotoxicity appears only after 
72-hours contact at higher concentrations (100 μM). Both sub cytotoxic ZA and LA doses decreased 3D (transwell 
assay) PCa cell migration rate. pAkt/Akt ratio is diminished by LA and, even if less strikingly, by ZA, in agreement 
with the respective inhibition migration ratios. Cells underwent migration test in mesenchymal stem cells – MSC – 
conditioned medium (MSC-CM), which significantly increases the rate of migration (210%± 2.2; P<0.05). Addition of 
both ZA and LA quenched the attractive effect of conditioned medium. Our results suggest that LA and, mostly, ZA 
have a direct toxic effect on cancer cells. Furthermore, they inhibit cellular migration even under attractive stimuli 
exerted by MSC, and this might contribute to explain their effect in limiting metastatization.
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Introduction
Prostate cancer (PCa) is the most frequent genitourinary 
tumor, representing 11% of the male malignancies in 
Europe, and is one of the leading causes of morbidity and 
mortality in the world [1].
Administration of GnRH agonist or other analogues 
(such as leuprolide acetate, buserelin, deslorelin, goserelin 
and istrerelin) is a well-established treatment of prostate 
cancer inducing a pharmacological castration [2] and 
resulting in cancer regression. Despite pharmacological 
treatment, the onset of metastatic dissemination 
represents, together with the development of androgen-
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independent growth, a critical progression step of human 
prostate cancer that largely determines the clinical course 
of the disease and survival of the patients [3]. Bone is 
a preferential site of metastases [4], which produce a 
crucial impact on patients’ functional status and quality 
of life due to significant pain and high risk of skeletal-
related events, including pathologic bone fractures (both 
vertebral and non-vertebral), spinal cord compression, 
surgery and radiotherapy to bone [5]. The burden of 
metastatic disease can be treated by administering a 
potent inhibitor of osteoclast activity such as zoledronic 
acid (ZA), a bisphosphonate widely used to treat skeletal 
complications of malignancy and considered the drug 
of choice for both the prevention and the treatment of 
bone mass loss. In vivo, it inhibits the release of growth 
factors from osteoblasts and bone marrow stromal cells 
[6]. Moreover, bisphosphonates modulate many other 
cellular and physiologic processes relevant to bone 
metabolism and tumor initiation and progression [7]. 
Prostate cancer cells tropism for the bone is the result of 
a sequential series of molecular events: bone metastases 
arise as a result of a crosstalk between metastatic cells, 
bone matrix, osteoblasts and osteoclasts, and cellular 
components of the bone marrow microenvironment. 
Among these, bone marrow mesenchymal stem cells 
(BM-MSCs) play a paramount role in the so-called 
metastatic niche [8, 9]. Prostate cancer cells migration 
can be influenced by MSC-conditioned medium soluble 
factors [8], and drugs normally used for prostate cancer 
treatment, such as zoledronic acid and leuprolide acetate, 
interact with this process [10]. We aimed at examining 
the effect of such molecules on the behavior of the 
human prostate cancer cell line DU-145 in an in vitro cell 
co-culture model of invasion assay. Cells were exposed to 
the drugs, alone or in combination, prior and/or during 
the migration test. We previously demonstrated that an 
up-regulation of Akt phosphorylation may exert a crucial 
role in DU-145 cell migration under conditioned medium 
stimulus [9]. Knowing that PI3-K/Akt signaling pathway 
plays a critical role in cell invasion and in modulation of 
cell migration [11], we also examined if zoledronic acid 
and leuprolide acetate modulate AKT level.
Materials and Methods
Materials
All reagents were purchased from Sigma (St. Louis, MO, 
USA) unless otherwise stated. Tissue culture plasticware 
was from Falcon (Franklin Lakes, NJ, USA). Zoledronic 
acid (ZA) [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-
diyl]bis (phosphonic acid) was generously provided by 
Novartis (Surrey, UK) and leuprolide acetate (LA) (N-[1-
[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-
[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxo-pentan-2-yl]
carbamoyl]-3-methyl-butyl]carbamoyl]-3-methylbutyl]
carbamoyl]-2-(4hydroxyphenyl)ethyl] carbamoyl]-
2-hydroxy-ethyl]carbamoyl]-2-(1H-indol-3-yl)ethyl]
carbamoyl]-2-(3H-imidazol-4-yl)ethyl]-5-oxopyrrolidine-
2-carboxamide) was from Takeda (Osaka, Japan).
Prostate cancer cell culture
Human androgen independent DU-145 prostate 
cancer cells were purchased from ATCC (Rockville, MD, 
USA). Cells were maintained at 37°C in a humidified 
5% CO2 atmosphere in RPMI 1640 containing 10 mL/L 
penicillin and streptomycin solution, NaHCO3 2 g/L (7.5% 
w/v), 10% Fetal Bovine Serum (FBS). 
Proliferation assay
DU-145 cells were seeded into flat-bottomed 96-well 
micro plates (1,000/100 μL culture medium/well) and 
allowed to attach overnight in complete medium before 
drugs addition. Drugs were added to culture medium, 
alone or in combination, testing various concentrations 
from 2.5 μM to 50 μM (ZA) [12] and from 0.5 μM to 100 
μM (LA) [13] for 24–96 hours, according to protocols. The 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay was performed as previously described 
[14]. Data (mean ± standard deviation) were the average 
values of 8 replicates. Each experiment was repeated 
thrice. Cell viability was expressed as percentage of living 
cells with respect to controls.
Mesenchymal stem cells isolation and MSC-CM 
collection
Bone marrow cells were obtained from femurs of 
adult rats as described in Mognetti et al, 2013. They 
were grown in complete αMEM containing 10% FBS, 
2 mM L-glutamine, 100 U/ml penicillin and 100 μg /mL 
streptomycin at 37 °C and 5% CO2for 3 days as previously 
described [9]. 
For migration assay, conditioned medium was 
collected after three days of culture, centrifuged at 4000 
rpm for 5 minutes at 4°C in order to eliminate cells and 
cellular debris, and used for migration assays or frozen.
Three-dimensional migration assay
Three-dimensional (3D) migration assay was used to 
measure the invasiveness of DU-145 cells in response 
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to various stimuli. Migration assays were performed in 
transwells (BD Falcon cell culture inserts incorporating 
polyethylene terephthalate – PET – membrane with 8.0 
μM pores, 6±2×104 pores /cm2) as previously described 
[9].
Briefly, 105 cells were resuspended in 200 μL of RPMI 
containing 2% FBS with or without drugs (zoledronic acid 
20 μM, leuprolide acetate 100 μM or both, representing 
non-toxic concentration at 24 hours as per the described 
viability assay) and then seeded in the upper chamber of a 
transwell; in the lower chamber, we added RPMI or MSC-
CM as detailed in Table 1. In some cases, before seeding 
cells were grown for 18 hours in presence of zoledronic 
acid 20 μM, leuprolide acetate 100 μM or both (Table 1). 
Table 1: Experimental conditions for migration assay
Pre-incubation 18 hours Migration test 6 hours 
none
RPMI
ZA 
LA 
LA
RPMI
LA 
ZA 
ZA
RPMI
ZA 
LA 
ZA + LA RPMI
none
MSC-CM
MSC-CM + ZA
MSC-CM + LA
LA= leuprolide acetate 100 µM 
ZA= zoledronic acid 20 µM
Transwells were placed in the incubator at 37 °C and 
5% CO2 for 6 hours and finally treated as detailed by 
Mognetti et al.[9].
Wells were photographed using a BRESSER Mikro Cam 
3 Mpx camera, with an optical microscope (Leica DC 
100) at 100 x. Five pictures were randomly chosen per 
well, and used to count the migrated cells with Image J 
software using cell-counter plug-in. Results from different 
experiments (performed at least three times in duplicate) 
were expressed as mean ± standard deviation. In order 
to avoid any cytotoxic effect potentially confounding 
migration results, we performed a cytotoxicity test at the 
same time and same conditions of every migration test.
Immunoassay to detect cytokine content in 
MSC-CM
Cytokine profiles in MSC-CM were determined using 
the Human Cytokine/ Chemokine Magnetic Bead Panel 
protocol from the “Milliplex®Human Cytokine 5 Plex” kit 
(Billerica, MA). The procedure was conducted according 
to the manufacturer’s protocol.
Briefly, the assay plates were washed with washing 
buffer, and shaken on an orbital plate shaker for 10 
minutes at room temperature. The washing buffer was 
decanted and the standards, assay buffer, or samples/
controls were mixed with serum matrix in each well, 
incubated overnight at 4°C on an orbital shaker with 
specific antibody to detect GM-CSF, MCP1/CCL2, IL-10, 
IFNγ, TNFα; well contents were then removed and wells 
washed. Biotinylated detection antibodies were then 
added and incubated for 1 hour at room temperature 
while shaking. After incubation, well contents were 
removed and streptavidin-phycoerythrin was added and 
incubated for 30 minutes at room temperature, then 
washed and resuspended in Sheath Fluid. Plates were 
read on the LuminexMagPix® machine and data were 
collected using the LuminexxPONENT® software (v.4.2); 
data analysis was performed using the Milliplex® Analyst 
software (v. 5.1).
Western blotting
Cells were seeded in 10 cm diameter Petri dishes, 
cultured until sub-confluence and then drugs were 
added (ZA 20 μM and LA 100 μM, to reproduce the same 
conditions of migration assay). After 6 hours incubation, 
cells were collected, treated and immunoblotted as 
detailed according to Mognetti et al. [9]. 
Blots were probed with primary polyclonal antibodies 
(Cell Signaling Technology, Danvers, MA, USA) suspended 
in TBS Tween 0.1% as follows: anti-Akt (mouse, 1:800), 
anti-pAkt (Ser473, rabbit, 1:500), anti-α5β1 (rabbit, 1:500, 
kindly provided by Prof. L. Primo, University of Turin) and 
anti-vinculin (developed in rabbit, Sigma). Vinculin was 
used as an internal control.
HRP-conjugated anti-mouse (Amersham-GE 
Healthcare, Buckinghamshire, UK) and anti-rabbit (Santa 
Cruz Biotechnology) were diluted (1:6000 and 1:8000, 
resp.) in TBS Tween 0.025%. Bands were quantified using 
the ImageJ software.
Results from different experiments (performed at 
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least three times in duplicate) were expressed as mean ± 
standard deviation. 
Phosphorylation levels of Akt were expressed as 
ratio pAkt/Akt. All data were expressed as percentage 
modification relative to control conditions.
Focal Adhesion
Cells were grown on Lab-Tek chamber slide (Nalge Nunc 
International, Rochester, NY, USA) until approximately 
50-60%confluent, then drugs were added (ZA 20 μM 
and LA 100 μM, to reproduce the same conditions of 
migration assay). After 6 hours cells were fixed with 4% 
paraformaldehyde in 1x PBS for 15-20 minutes at room 
temperature and then treated with the Actin Cytoskeleton 
and Focal Adhesion Staining Kit (Millipore, Burlington, 
MA, USA) according to the manufacturer instructions. The 
samples were finally mounted with a Dako fluorescent 
mounting medium (DAKO) and analyzed by aLSM 510 
confocal laser microscopy system (Zeiss, Jena, Germany).
Statistical analysis
All the data in this study were shown as the mean ± 
standard deviation. Statistical analyses were performed 
by One-way ANOVA, with Dunnett’s post-tests, or two-
way ANOVA using Graph Pad Prism version 5.00 for 
Windows (Graph Pad Software, San Diego California USA).
Coefficient of Drug Interaction (CDI) was used to define 
the type of interactions between the employed drugs. CDI 
was calculated by means of the equation: CDI = AB/(A × B), 
where AB is the relative cell migration of the combination; 
A or B, relative cell migration of the single agent. CDI < 1 
indicates a synergistic effect; CDI = 1 indicates an additive 
effect; CDI > 1 indicates an antagonistic effect. 
Results
Effect of zoledronic acid, leuprolide acetate and 
combination of both on cell proliferation
Incubation up to 24 hours with 20 and 40 μM zoledronic 
acid induced a weak cytotoxic effect on DU-145 (Figure1A). 
A statistically significant cytotoxicity appears after 48 
hours of incubation, already at the 5μM concentration.
Leuprolide acetate displayed no cytotoxicity on DU-145 
cells (Figure1B), within the concentration range tested, 
after 24 and 48 hours of incubation. 
A significant toxicity is appreciable only after 72 hours 
of incubation from 5 µM on.
Addition of leuprolide acetate 100 μM did not increase 
zoledronic acid cytotoxicity at any concentration after 48 
hours incubation (Figure 1C).
Figure 1:  Effect of zoledronic acid and leuprolide acetate 
on DU-145 growth. (A) Proliferation assay after 24, 48 and 
72 hours culture in presence of increasing concentration 
of zoledronic acid (2.5-50 µM). (B) Proliferation assay after 
24, 48 and 72 hours culture in presence of increasing 
concentration of leuprolide acetate (0.5-100 µM). (C) Effect 
of LA 100 µM and ZA (0-40 µM), alone or in combination, 
on DU-145 cell after 48 hours incubation. 
*=P<0.05 vs control.
3D migration assay 
Both drugs (ZA and LA) decreased migration rate of 
DU-145 cells when compared to control (Figure 2). At 
these conditions, leuprolide acetate was significantly 
more effective than ZA in inhibiting cell migration. The 
simultaneous presence of the two drugs influenced 
migration less than each single drug; association 
decreased the efficiency of leuprolide acetate alone and 
did not seem to differ from incubation with zoledronic 
acid alone.
 Single drug pre-incubation did not potentiate the effect 
of simple incubation, in any case (Figure 2).The effects 
of any single drug were not significantly potentiated by 
any pre-incubation, even, in some cases, abolished (pre-
incubation with ZA or LA and pre-incubation with ZA 
followed by migration with ZA).
 When cells were pre-incubated with the single drugs 
before migration test performed in control medium, 
migration was not inhibited at all. On the other hand, 
when cells were pre-incubated with both drugs, migration, 
even if occurring in RPMI, was inhibited as much as when 
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cells were not pretreated but incubated with both drugs 
simultaneously. MSC-CM significantly increased the rate 
of migration towards control medium, and the addition of 
both drugs quenched the attractive effect of conditioned 
medium (Figure 2). 
Figure 2: Three-dimensional migration. Migration 
rate after incubation or pre-incubation with drugs and/
or in conditioned media (CM) compared to control. 
Migration is expressed in arbitrary units. 
 *=P<0.05 vs control; ***= P<0.001 vs control; 
●=P<0.001 vs ZA; #=P<0.001 vs LA+ZA.
Drug interaction
CDI results suggest an antagonistic effect in the 
incubation LA + ZA, slightly additive for pre-incubation ZA 
+ incubation LA and synergistic for pre-incubation LA + 
incubation ZA, as reported in Table 2.
Table 2: Drug interactions. CDI < 1 indicates a 
synergistic effect; CDI = 1 indicates an additive effect; 
CDI > 1 indicates an antagonistic effect. 
AB A B CDI
Incubation LA+ 
ZA
incubation 
ZA
incubation 
LA
2,02
Pre-incubation 
ZA + incubation 
LA
Pre- incu-
bation ZA
incubation 
LA
1,02
Pre-incubation 
LA + incubation 
ZA
P r e - i n c u -
bation LA
incubation 
ZA
0,58
Cytokines content in MSC-CM
Cytokines were detected in MSC-CM as follows:
GM-CSF: 93.40 pg/ml
MCP1/CCL2: 12.95 μg/ml
IL-10: 1.81 pg/ml
IFNγ: 30.75 pg/ml
TNFα: 40.34 pg/ml
pAkt/Akt Ratio after Drugs Incubation
LA slightly inhibited Akt phosphorylation compared 
to control (Figure 3) after 6 hours incubation, though ZA 
effect was more evident.
Figure 3: Drugs effect on pAkt/Akt in DU-145 cell 
line after 6 hours of incubation with LA 100 µM or ZA 
20 µM, as detected by western blot (one representative 
experiment). Vinculin as internal control.
Adhesion Molecules Expression 
The expression of α5β1 as detected by western blot 
analysis was not modified by 6 hours incubation in ZA 20 
μM or LA 100 μM, as shown in figure 4. 
Figure 4: Drugs effect on α5β1 expression in DU-145 
cell line after 6 hours of incubation with LA 100 µM or ZA 
20 µM, as detected by western blot. Vinculin as internal 
control.
Immunocytochemistry analysis was performed after 6 
hours of culture to qualitatively evaluate cell adhesion and 
morphology. In order to obtain a more detailed evaluation 
of cell adhesion, the actin cytoskeleton and focal adhesion 
complex were stained using TRITC-conjugated phalloidin 
and antivinculin antibody, respectively. 
No gross difference was detectable in the three 
different culture conditions, in terms of dimension, 
orientation of the actin cytoskeleton or exact location of 
focal adhesion sites. Vinculin-positive sites were observed 
both on control and treated cells, and their distribution 
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was alike (data not shown).
Discussion
In this work, we demonstrate that ZA and LA inhibits, 
in vitro, the proliferation of human prostate cancer 
cells: this is particularly true for ZA, whose cytotoxicity 
appears already after 48- hours incubation and at lower 
concentrations than those necessary to observe a LA-
induced cytotoxic effect. Since patients often receive both 
drugs, we searched for eventual interactions between 
the two molecules in vitro. Therefore, we incubated DU-
145 cells with both drugs contemporaneously (at variable 
concentrations of ZA). No synergistic effect was induced 
by the simultaneous incubation with ZA and LA on cells. 
Besides cytotoxicity, we wondered if ZA and LA 
could have other effects on prostate cancer cells in 
vitro. Therefore, because of its relevance on metastasis 
phenomenon, we decided to investigate tridimensional 
migration by means of the transwell assay and the 
evaluation of Akt phosphorylation level.
Both ZA and LA decreased in Akt phosphorylation in 
6 hours, but while LA inhibition was faint and far from 
significance, ZA effect was irrefutable. The timing and the 
effect, greater than LA- induced, are both in agreement 
with what observed in inhibition of cell migration (Figure 
2). 
Because of its important role in driving the chemotactic 
affinity of prostate cancer cells to human bone marrow 
mesenchymal stromal cells [15] we decided to check if 
ZA and LA had an effect in modulating the expression of 
α5β1. According to our western blot analysis neither drug 
affected α5β1expression in 6 hours; analogously, neither 
drug modified the expression or localization of exact 
location of focal adhesion sites, nor orientation of the 
actin cytoskeleton. Hence, this is probably not the way by 
which LA and (even more) ZA hamper DU-145 migration.
Furthermore, co-incubation with ZA and LA raises no 
synergistic effect (Table 2); rather, LA effect seems to 
be significantly reduced by the presence of ZA. On the 
other hand, pre-incubation with LA (but not with ZA) 
significantly potentiates inhibitory migration properties 
of both LA and ZA in a synergistic manner. Nevertheless, 
the simultaneous presence of the drugs has to induce 
some effect on cell migratory properties, since when cells 
were pre-incubated with the single drugs their migration 
in culture medium was not inhibited at all, while 18-hours 
pre-incubation with ZA and LA significantly decreased 
their migration, even in RPMI. This might suggest that 
incubation with each drug singularly can cause not 
relevant/reversible changes, which cells are able to 
repair, while specific pre-incubation and/or specific 
drugs sequences (in particularly pre-incubation with 
LA followed by incubation with ZA) could lead to hard 
reversible changes affecting cell migration. We do not 
know, at present, how to explain this phenomenon, but a 
durable effect of the simultaneous presence of ZA and LA 
is probably worth further investigations. 
About the ability to migrate more towards MSC-
CM, it has been shown that migration and formation 
of metastases by prostate cancer cells in vivo is largely 
influenced by several factors produced by bone cells 
[16,17,18,19,20]. We observed a massive migratory 
increase under MSC-CM stimulus. It is interesting to note 
that both ZA and LA inhibit DU-145 3D-migration at the 
same magnitude also when cells undergo MSC-CM stimuli 
(Figure 2). According to the literature, we found that the 
MSC-CM contains several factors involved in cancer cell 
survival and migration, such as TNFα, MCP1/CCL2 [16-18] 
and GM-CSF [21]. Aggressive cancer cell lines such as DU-
145 and PC3 express a higher amount of CCL2-specific 
receptor CCR2 compared with the less aggressive cancer 
cells such as LNCaP or non-neoplastic PrEC and RWPE-1 
cells [22]; a positive correlation has also been established 
between CCR2 expression and prostate cancer 
progression [18]. Furthermore, Rivas and coll. [21] shown 
that prostate cancer cells express functional high-affinity 
GM-CSF receptors and therefore this hematopoietic 
growth factor may have an effect on prostate carcinoma 
cells. The increased expression of GM-CSF receptors in 
prostatic hypertrophy and neoplastic prostate ephitelium 
suggests a relationship between prostatic epithelial cell 
growth and GM-CSF [21]. At least, as shown by Gao and 
coll [23], TNFα factor in endothelial cells may increase the 
activation and ligation of αvβ3 integrins [23] to facilitate 
cell migration, and regarding prostate cancer activation 
have a central role in prostate cancer metastatization 
[24].
As previously reported in literature, most of 
these factors are affected by action of ZA and LA 
[25,26,27,28,29,30]. In particular, a direct correlation 
between GM-CSF and MCP-1 decreased levels and cell 
invasiveness has been demonstrated [25,28]. On the 
basis of these observations, we could speculate that, 
as demonstrated in other systems, it can be confirmed 
in our own that the action of ZA and LA in decreasing 
migration could be both directed to the tumor cells and 
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indirectly on potential metastatic niche.
Conclusions
Our results suggest that: (i) drugs in use in vivo for 
prostate cancer treatment have a direct effect on prostate 
cancer cells proliferation, and this could contribute to 
justify the results obtained in vivo; (ii) effect of drugs 
overlapping is difficult to predict a priori; we are unable, 
with data at our disposal, to identify a regimen that 
clearly enhances the effect of the two drugs. However, 
we have shown that specific co-incubation prolongs 
inhibitory effect on prostate cancer cells migration; (iii) 
drugs affect migratory ability of prostate cancer cells, 
and this could contribute to justify their limiting effect 
of in vivo metastases (mostly due to LA). This inhibition, 
though, does not seem to be mediated by a change in 
the expression of α5β1 or focal adhesion molecules 
distribution; (iv) in the same way ZA and LA diminish the 
chemoattractive effect of the bone marrow mesenchymal 
stem cells and, hence, the potential role that they can 
play in the phenomenon of metastasis; (v) ZA-induced 
decrease in cell migration, compatible with action on the 
PI3K/Akt pathway [31].
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